1. A fluoropolymer process aid composition comprising a) fluoropolymer and b) polycaprolactone having a number average molecular weight in the range of 2000 to 10000.
2. A composition of claim 1 wherein said composition has a weight ratio of polycaprolactone to fluoropolymer of up to 5:1.
3. A composition of claim 1 wherein said polycaprolactone has a number average molecular weight between 2000 and 4000.
4. A composition of claim 1 wherein said fluoropolymer is a fluoroelastomer comprising a copolymer of vinylidene and a comonomer selected from the group consisting of hexafluoropropylene, chlorotrifluoroethylene, 1-hydropentafluoropropylene, 2-hydropentafluoropropylene and tetrafluoroethylene.
5. A composition of claim 1 wherein said fluoropolymer is a semi-crystalline fluoropolymer selected from the group consisting of poly(vinylidene fluoride), tetrafluoroethylene homopolymer, a copolymer of tetrafluoroethylene and hexafluoropropylene and a copolymer of tetrafluoroethylene and propylene.
6. A composition of claim 1 wherein said fluoropolymer is a fluoroelastomer comprising a copolymer of tetrafluoroethylene and propylene.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A nitric oxide donating polymer comprising:
at least one polymerizable monomer selected from the group comprising n-butyl methacrylate, n-hexyl methacrylate, cyclohexyl methacrylate, 2-ethylhexyl methacrylate, and; at least one vinyl monomer comprising at least one acetate group; and wherein said acetate group binds at least one diazeniumdiolate group.
2. The nitric oxide donating polymer of claim 1 wherein said polymer comprises Formula 1:
wherein R4 and R5 are independently selected from the group comprising C1 to C20 straight chain alkyls, C3 to C8 cycloalkyls, C2 to C20 alkenyls, C2 to C20 alkynyls, C2 to C14 heteroatom substituted alkyls, C2 to C14 heteroatom substituted cycloalkyls, C1 to C10 multiple amine containing-hydrocarbons, C4 to C10 substituted aryls and C4 to C10 substituted heteroatom substituted heteroaryls; R1, R2 and R3 are independently a hydrogen or said diazeniumdiolate group; a, b, and c are respectively 1-2000, 1-2000, and 1-2000.
3. The nitric oxide donating polymer of claim 1 wherein said polymer comprises Formula 3:
wherein R1, R2 and R3 are independently a hydrogen or said diazeniumdiolate group; a, b, and c are respectively 1-2000, 1-2000, and 1-2000.
4. The nitric oxide donating polymer of claim 1 wherein said polymer has the general structure of Formula 5:
wherein R1, R2 and R3 are independently a hydrogen or said diazeniumdiolate group; a, b, and c are respectively 1-2000, 1-2000, and 1-2000.
5. The nitric oxide donating polymer of claim 1 wherein said vinyl monomer is vinyl acetate.
6. The nitric oxide donating polymer of claim 1 wherein the polydispersity index is between 1.1 and 5.0.
7. The nitric oxide donating polymer of claim 1 wherein the glass transition temperature is between \u221230 and 150 C.
8. A medical device having a coating comprised of said nitric oxide donating polymer of claim 1.
9. The nitric oxide donating polymer of claim 8 wherein said implantable medical device is selected from the group consisting of vascular stents, shunts, vascular grafts, stent grafts, heart valves, catheters, pacemakers, pacemaker leads, bile duct stents and defibrillators.
10. The nitric oxide donating polymer according to claim 8 wherein said polymer can release at least one drug in addition to nitric oxide.
11. The nitric oxide donating polymer according to claim 10 wherein said at least one drug is selected from the group consisting of anti-proliferatives, estrogens, chaperone inhibitors, protease inhibitors, protein-tyrosine kinase inhibitors, leptomycin B, peroxisome proliferator-activated receptor gamma ligands (PPAR\u03b3), hypothemycin, nitric oxide, bisphosphonates, epidermal growth factor inhibitors, antibodies, proteasome inhibitors, antibiotics, anti-inflammatories, anti-sense nucleotides and transforming nucleic acids.
12. The nitric oxide donating polymer according to claim 10 wherein said drug comprises at least one compound selected from the group consisting of sirolimus (rapamycin), tacrolimus (FK506), everolimus (certican), temsirolimus (CCI-779) and zotarolimus (ABT-578).
13. A medical device having a structure wherein said structure comprising said nitric oxide donating polymer of claim 1.
14. The nitric oxide donating polymer of claim 13 wherein said implantable medical device is selected from the group consisting of vascular stents, shunts, vascular grafts, stent grafts, heart valves, catheters, pacemakers, pacemaker leads, bile duct stents and defibrillators.
15. The nitric oxide donating polymer according to claim 13 wherein said polymer can release at least one drug in addition to nitric oxide.
16. The nitric oxide donating polymer according to claim 15 wherein said at least one drug is selected from the group consisting of anti-proliferatives, estrogens, chaperone inhibitors, protease inhibitors, protein-tyrosine kinase inhibitors, leptomycin B, peroxisome proliferator-activated receptor gamma ligands (PPAR\u03b3), hypothemycin, nitric oxide, bisphosphonates, epidermal growth factor inhibitors, antibodies, proteasome inhibitors, antibiotics, anti-inflammatories, anti-sense nucleotides and transforming nucleic acids.
17. The nitric oxide donating polymer according to claim 15 wherein said drug comprises at least one compound selected from the group consisting of sirolimus (rapamycin), tacrolimus (FK506), everolimus (certican), temsirolimus (CCI-779) and zotarolimus (ABT-578).